Asset Details
Do you wish to reserve the book?
Dosimetric Planning Comparison for Left Ventricle Avoidance in Non-small Cell Lung Cancer Radiotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dosimetric Planning Comparison for Left Ventricle Avoidance in Non-small Cell Lung Cancer Radiotherapy
Do you wish to request the book?
Dosimetric Planning Comparison for Left Ventricle Avoidance in Non-small Cell Lung Cancer Radiotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dosimetric Planning Comparison for Left Ventricle Avoidance in Non-small Cell Lung Cancer Radiotherapy
2024
Overview
Radiation may unintentionally injure myocardial tissue, potentially leading to radiation-induced cardiac disease (RICD), with the net benefit of non-small cell lung cancer (NSCLC) radiotherapy (RT) due to the proximity of the lung and heart. RTOG-0617 showed a greater reduction in overall survival (OS) comparing higher doses to standard radiation doses in NSCLC RT. V
Heart has been reported as an OS predictor in the first- and fifth-year follow-ups. A worsening OS trend was reported in another study where the mean left ventricle dose (mean LV) was ≥14.5 Gy. It is therefore important to spare the heart, specifically the LV, from radiation. Furthermore, dose-limiting factors toward the normal lung should be accounted for to prevent radiation-induced lung injury.
The LV and left anterior descending artery (LAD) were also contoured on the average four-dimensional computed tomography (4D-CT) dataset that contained clinically defined targets and normal structures for stage III NSCLC RT. The prescribed treatment plans (n=15) were retrospectively optimized with the clinical goals of minimizing the mean LV and mean heart dose while maintaining the dose constraint of V
Lung ≤30% and V
PTV ≥95%. Dose-volume histograms were used to compare the heart and lung dosimetric parameters between the delivered and reoptimized RT plans.
A significant reduction (p≤0.044) was observed in the mean LV, mean heart dose, mean LAD dose, max LAD dose, and V
Heart from the reoptimized RT plans. V
Lung ≤30% and V
PTV ≥95% were maintained, and no differences were observed in the mean lung, V
Lung, V
Lung, mean esophagus, and max cord.
Minimizing the LV dose in NSCLC RT plans is achievable and dosimetrically advantageous for the heart while maintaining dose constraints to the normal lung and maximizing tumor control. Radiation dose reduction to cardiac substructures may decrease the RICD risk in NSCLC patients.
Publisher
Springer Nature B.V,Cureus
Subject
